1,2-BIS(DIETHYLPHOSPHINO)ETHANE

We are 1,2-BIS(DIETHYLPHOSPHINO)ETHANE CAS:6411-21-8 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:  1,2-BIS(DIETHYLPHOSPHINO)ETHANE
CAS.NO:6411-21-8
Molecular Formula:C10H24P2
Molecular Weight:206.24500

Synonyms:
2-diethylphosphanylethyl(diethyl)phosphane

Physical and Chemical Properties:
Density: 0.884
Boiling point: 124-126 ° C (10 mmHg)
Flash point: 124-126 ° C / 10mm
Refractive index: 1.508-1.51

Specification:
Appearance:Colorless Liquid
Purity:≥98%

Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Keep the container tightly closed, put it in a tight dispenser, and store in a cool, dry place.
Application:pharmaceutical intermediates.

 1,2-BIS(DIETHYLPHOSPHINO)ETHANE


Related News: In April 2019, Glenmark had received approval from the Drugs Controller General of India (DCGI) for Remogliflozin Etabonate after successfully completing Phase-3 clinical trials.Methyl chloroacetate CAS:96-34-4 In April 2019, Glenmark had received approval from the Drugs Controller General of India (DCGI) for Remogliflozin Etabonate after successfully completing Phase-3 clinical trials.5445-17-0 “CAR T-cell therapy continues to deliver remarkable outcomes for patients with hematologic malignancies, and next-generation approaches are needed to enable broad and timely patient access and reduce the cost and complexity of therapy,” said Scott Wolchko, President and Chief Executive Officer of Fate Therapeutics.Raspberry ketone glucoside CAS:38963-94-9 “CAR T-cell therapy continues to deliver remarkable outcomes for patients with hematologic malignancies, and next-generation approaches are needed to enable broad and timely patient access and reduce the cost and complexity of therapy,” said Scott Wolchko, President and Chief Executive Officer of Fate Therapeutics.“CAR T-cell therapy continues to deliver remarkable outcomes for patients with hematologic malignancies, and next-generation approaches are needed to enable broad and timely patient access and reduce the cost and complexity of therapy,” said Scott Wolchko, President and Chief Executive Officer of Fate Therapeutics.

Related Products
Product Name
1-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-enyl)methyl)piperazine View Details
1,1,1,2,2,4,5,5,5-nonafluoro-4-(trifluoromethyl)pentan-3-one Cas:756-13-8 View Details
[dimethyl-[3-(oxiran-2-ylmethoxy)propyl]silyl]oxy-dimethyl-[3-(oxiran-2-ylmethoxy)propyl]silane View Details
5-bromo-2-chloro-4’-ethoxydiphenylmethane manufacturer 3,3,3-trifluoroprop-1-ene Cas:677-21-4 manufacturer 1-Bromo-4-chloro-2-fluorobenzene manufacturer 4-ethenyl-2,3-dihydro-1-benzofuran manufacturer 3-Ethyl-5-(2-Hydroxyethyl)-4-Methylthiazolium Bromide manufacturer